Skip to main content

Table 1 Patient and Tumor characteristics

From: Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

Nr. Age Range Symptoms Duration of symptoms Tumor location in contact with CSF space Contrast enhancement Relevant patient history
1 70–79 general weakness, decline in overall health few weeks multifocal (left basal ganglia, right thalamus, hemispheres) yes Sparce, partial no immunosuppression
2 40–49 general weakness, decline in overall health few weeks multifocal (basal ganglia, brainstem / medulla, cerebellar peduncles) yes Sparce, partial HIV positive, previous EBV infection
3 60–69 gait disturbance, halluzinations 1,5 weeks right basal ganglia yes Strong, homogenous Melanoma of the scalp 4 years prior (excision only, no radiation/ chemo)
4 70–79 syncope, left hemiparesis, reduced alertness and arousal 2 weeks bilateral basal ganglia, velum interpositum yes Strong, homogenous no immunosuppression
5 70–79 right hemiparesis, reduced alertness, general weakness 3 weeks left basal ganglia yes Strong, homogenous no immunosuppression
6 70–79 right hand weakness, speech arrest 4 weeks No tumor (contrast-enhancing meninges, left periventricular changes in T2 flair images) yes Strong (meninges) systemtic B-cell lymphoma, full remission, no recurrence after 6 cycles of R-CHOP 8 years prior; rheumatoid arthritis (MTX-therapy)